Aethlon Medical | 10-Q: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -3.74.

EBIT: As of FY2026 Q2, the actual value is USD -1.533 M.

Segment Revenue

• No revenue was recognized during the six months ended September 30, 2025.

Operational Metrics

• Net Loss: The net loss for the three months ended September 30, 2025, was $1,487,100, compared to $2,806,973 for the same period in 2024.
• Operating Expenses: Operating expenses for the three months ended September 30, 2025, were approximately $1,510,000, compared to $2,902,000 for the same period in 2024.
• General and Administrative Expenses: General and administrative expenses for the three months ended September 30, 2025, were approximately $739,000, compared to $958,000 for the same period in 2024.
• Professional Fees: Professional fees for the three months ended September 30, 2025, were approximately $393,796, compared to $570,845 for the same period in 2024.
• Payroll and Related Expenses: Payroll and related expenses for the three months ended September 30, 2025, were approximately $594,611, compared to $1,372,899 for the same period in 2024.
• Research and Development Expenses: Research and development expenses for the three months ended September 30, 2025, were approximately $294,318, compared to $261,486 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: Net cash used in operating activities for the six months ended September 30, 2025, was approximately $3,374,000, compared to approximately $3,962,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: Net cash provided by financing activities for the six months ended September 30, 2025, was approximately $3,736,000, compared to approximately $5,375,000 for the same period in 2024.

Unique Metrics

• Australian R&D Tax Incentive: The company recognized approximately $218,000 related to the Australian R&D tax incentive during the three months ended September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company is focused on advancing the Hemopurifier® through clinical trials in Australia and exploring additional clinical contexts based on its mechanism of action and preclinical findings. The company aims to generate timely clinical data to support a potential Premarket Approval (PMA) trial.
• Non-Core Business: The company decided not to proceed with the oncology clinical trial in India to conserve resources and concentrate efforts on the Australian oncology trial.
• Priority: The company is actively evaluating a range of strategic and financing options to extend its cash runway and support ongoing operations, including potential equity offerings and other funding opportunities.